tag:blogger.com,1999:blog-4287560491211025099.post4484014906629355992..comments2023-09-22T08:24:01.913-04:00Comments on Antibiotics - The Perfect Storm: Will Astra-Zeneca be Next?David Shlaeshttp://www.blogger.com/profile/00228776693058791618noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-4287560491211025099.post-8312618946555820322013-03-25T08:32:16.237-04:002013-03-25T08:32:16.237-04:00I guess I find that a little hard to understand. ...I guess I find that a little hard to understand. If ceftaroline really works for MRSA (and it looks like it does) then who wouldn't want to use a cephalosporin that is safer and may be more efficacious than a glycopeptide? But then, the UK is starting to look a little like Japan to me - inscrutable. David Shlaeshttps://www.blogger.com/profile/00228776693058791618noreply@blogger.comtag:blogger.com,1999:blog-4287560491211025099.post-77789474860797912182013-03-25T03:02:32.121-04:002013-03-25T03:02:32.121-04:00I'm not surprised. In the UK, AZ launch ceftar...I'm not surprised. In the UK, AZ launch ceftaroline and we say it's a cephalosporin so we can't use it. Regional benchmarking showed no difference in Cdiff rates based on cephalosporin usage rates. We need to have more diversity in our patients, and avoid higher risk antibiotics in higher risk groups where possible. Philiphttps://www.blogger.com/profile/07701757232551654002noreply@blogger.com